Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests to support cancer care across multiple stages of the disease. Its current portfolio includes genomic profiling for advanced cancer, minimal residual disease and recurrence monitoring, and screening focused on earlier detection. The company also provides companion diagnostic and development services for biopharmaceutical partners, using clinico-genomic data, real-world evidence, and analytics to help guide therapy development and clinical decision-making. Guardant Health serves oncologists, patients, laboratories, and drug developers through a platform built around molecular testing and data interpretation. Headquartered in Palo Alto, California, Guardant Health plays a significant role in the expanding market for liquid biopsy and precision diagnostics, where noninvasive testing is increasingly used to inform treatment selection and cancer monitoring.